We are live on ! Find out more
ALDR

Alder Biopharmaceuticals
ALDR

Delisted

ALDR was delisted on the 21st of October, 2019.

Back to rankings

143 hedge funds and large institutions have $1.75B invested in Alder Biopharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 4 → 8 (+4)

65% more capital invested

Capital invested by funds: $1.06B → $1.75B (+$693M)

52% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 31

13% more funds holding

Funds holding: 127 → 143 (+16)

5% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 38

95% less call options, than puts

Call options by funds: $5.68M | Put options by funds: $115M

Holders
143
Holders Change
+16
Holders Change %
+12.6%
% of All Funds
3.14%
Holding in Top 10
8
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+100%
% of All Funds
0.18%
New
47
Increased
36
Reduced
38
Closed
31
Calls
$5.68M
Puts
$115M
Net Calls
-$109M
Net Calls Change
-$109M

Top Buyers

1
FCM
Farallon Capital Management
California
+$47.6M
2
CC
Carlson Capital
Texas
+$40.6M
3
DKCM
Davidson Kempner Capital Management
New York
+$37.9M
4
AAM
Alpine Associates Management
Florida
+$35.3M
5
PCM
Pentwater Capital Management
Florida
+$35.3M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$121M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$80.8M
3
SC
Samlyn Capital
New York
-$31.1M
4
Citadel Advisors
Citadel Advisors
Florida
-$28M
5
Goldman Sachs
Goldman Sachs
New York
-$22.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
1
Redmile Group
California
$155M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$123M -$1.42M -124,124 -2%
BlackRock
3
BlackRock
New York
$120M -$6.52M -570,353 -8%
BG
4
Bellevue Group
Switzerland
$84.7M +$4.27M +373,660 +9%
FCM
5
Farallon Capital Management
California
$78.6M +$47.6M +4,165,000 New
CC
6
Carlson Capital
Texas
$67M +$40.6M +3,550,500 New
DKCM
7
Davidson Kempner Capital Management
New York
$62.5M +$37.9M +3,312,203 New
AAM
8
Alpine Associates Management
Florida
$58.2M +$35.3M +3,086,227 New
PCM
9
Pentwater Capital Management
Florida
$58.1M +$35.3M +3,082,920 New
State Street
10
State Street
Massachusetts
$54.4M -$4.42M -386,136 -12%
MAM
11
Melqart Asset Management
United Kingdom
$50.5M +$30.7M +2,680,000 New
Millennium Management
12
Millennium Management
New York
$50.1M +$26.3M +2,300,799 +650%
FCMI
13
Foresite Capital Management III
California
$45.1M -$6.27M -548,518 -19%
PSAMP
14
P. Schoenfeld Asset Management (PSAM)
New York
$44.7M +$27.1M +2,372,000 New
PAI
15
Palo Alto Investors
California
$35.1M – – –
Goldman Sachs
16
Goldman Sachs
New York
$35.1M -$22.8M -1,989,634 -52%
Norges Bank
17
Norges Bank
Norway
$28.3M +$1.42M +124,395 +9%
Man Group
18
Man Group
United Kingdom
$25.4M +$15.4M +1,344,632 New
TAL
19
TIG Advisors LLC
New York
$24.9M +$15.1M +1,319,643 New
RSCM
20
Rock Springs Capital Management
Maryland
$24.5M -$3M -262,300 -17%
UOC
21
UBS O'Connor
Illinois
$23.5M +$14.3M +1,248,003 New
TGHSA
22
TPG Group Holdings (SBS) Advisors
Texas
$23.4M – – –
LPC
23
Lion Point Capital
New York
$22.7M – – –
Tudor Investment Corp
24
Tudor Investment Corp
Connecticut
$21M +$12.5M +1,089,040 +4,136%
Ameriprise
25
Ameriprise
Minnesota
$18.7M -$4.76M -415,872 -30%
1
2 3 4 5

ALDR Hedge Fund Activity: Q3 2019 in Review

143 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q3 2019, worth a combined $1.75B — up 65% from $1.06B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ALDR positions and 31 closed out — a net gain of 16 holders — while 36 added to existing stakes and 38 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $47.6M. The largest seller was Wellington Management Group, exiting entirely with an estimated $121M sold.

  • 143 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q3 2019, up from 127 in Q2 2019.
  • Funds reported $1.75B of Alder Biopharmaceuticals stock for Q3 2019, up 65% quarter-over-quarter.
  • 47 funds opened new Alder Biopharmaceuticals positions in Q3 2019 and 31 closed out, a net change of +16 holders.
  • The largest Alder Biopharmaceuticals buyer in Q3 2019 was Farallon Capital Management, an estimated $47.6M added.
  • The largest Alder Biopharmaceuticals seller in Q3 2019 was Wellington Management Group, an estimated $121M sold.

Based on aggregated 13F filings for Q3 2019.